1. Bryan Richard Soper, Ph.D.
San Francisco, CA • 415.265.6202 • brsoper@gmail.com
PROFILE
 Specific knowledge of small molecule drugs and biologics in regards to mechanism of action,
clinical efficacy and adverse events, as well as the commercial marketplace
 Experience mining big data and distilling relevant information for effective communication to
different target audiences
 Highly collaborative and able to liaise easily with internal and external stakeholders
WORK EXPERIENCE
Medical Writer at Health Interactions Jan. 2016 – Present
 Perform competitive intelligence contract work for Genentech/Roche
 Develop content and presentation materials for competitive threat assessment
workshops to analyze competitor’s clinical trials and assess the potential efficacy and
probability of launch of therapies
 Analyze the specificity/sensitivity of diagnostics, molecular and clinical features of
patient’s tumors, to render a quantitative assessment of a drug’s likelihood to achieve
frontline approval in a new indication that was missed by a panel of experts
 Write quarterly reports and perform quality control on standard of care tables for five
Hematology / Oncology disease indications
PATENT
Bryan Soper (Sole Inventor and Assignee)
Patent number (France, U.K., Switzerland) : 1999668 Registered: Nov. 12, 2014
German patent number: 602007037897.4 Registered: Nov. 12, 2014
Japanese patent number: 5301424 Registered: June 28, 2013
International Application No. PCT/US2007/006563 Filed: March 15, 2007
Methods of Screening for and Mapping Phenotypic and Genotypic Variations in Cultured Cells
 Employs a functional genomics means of discovering targets relevant to disease
 Applicable in diseases capably modeled in single cells (e.g. cancer, HIV, Hep C)
 Evaluates the value of a gene target against the current standard of care before
incurring the expense of therapeutic biologic or small molecule development
BIG DATA ANALYSIS
Meta-Analysis of Cancer Models and Clinical Outcomes 2010 –2011
 Analyzed 324 pre-clinical treatments in 1455 experiments to test correlation to the
outcomes of 104 clinically tested treatments
 Identified a dose-restricted set of data that demonstrates a statistically significant
correlation (r = -0.646, p = 0.002814) between pre-clinical experiments to phase 3
median overall survival benefit in patients
Meta-Analysis of Clinical Trial Outcomes 2012 – 2013
 Analyzed 500 new investigational drugs in 1834 clinical trials listed on ClinicalTrials.Gov
to assess the need for new/better targets in non-small cell lung cancer (NSCLC)
 Identified a mere 0.8% success rate in NSCLC phase 3 clinical trials in 12 years

2. BRYAN SOPER, PHD PAGE 2
ENTREPRENEURIAL EXPERIENCE
Business plan pitches 2005 – 2014
 Secured meetings with leaders to pitch a business plan for drug development at:
o Roche (Head of Venture and Innovation, Jason Coloma)
o Gilead Sciences Inc. (Senior Director of Biology, Thomas Cihlar)
o Genomics Institute of the Novartis Research Foundation (Director, Peter Schultz)
o UCSF Comprehensive Cancer Center (Director, Frank McCormick)
o UCSF Center for AIDS Research (Co-director, Warner Greene)
RELATED EXPERIENCE
Innovation Accelerator Steering Committee member 2006 – 2008
RESEARCH EXPERIENCE
Postdoctoral Scholar 2007 – 2010
Staff Research Associate II 2006 – 2007
University of California, San Francisco - James McKerrow, Ph.D., M.D.
 Employed patented method to identify new drug targets for HIV/AIDS, Leishmaniasis,
and Chagas disease
 Investigated viral infection for transgenesis in the human parasite Schistosoma mansoni
 Collaborated with Dr. Joseph DeRisi’s lab to identify endemic viruses by microarrays
 Mentored students and peers by providing scientific direction and technical assistance
 Initiated and organized a weekly meeting to provide scientific mentoring
Ph.D. Dissertation Research 1998 - 2005
Sloan-Kettering Institute - Kathryn V. Anderson, Ph.D.
 Characterized pattern recognition receptors in the immune systems of flies and mice
 Deleted a gene in mouse embryonic stem cells by homologous recombination to derive
a mouse deficient in a presumed pattern recognition receptor
 Conducted genetic screens to identify genes involved in Drosophila innate immunity
 Taught molecular genetics course as a graduate student instructor
EDUCATION
Ph.D., Molecular Biology 1998 - 2005
Cornell University, Weill Graduate School of Medical Sciences
Sloan-Kettering Institute, New York, NY
B.A., Molecular and Cell Biology emphasis in Genetics 1994 - 1997
University of California, Berkeley, CA
UC Berkeley MCB graduate with honors (1997)
California Alumni Leadership Scholar (1994-1997)
VOLUNTEER WORK
Head Soccer Coach (US Soccer Federation E License) 2013 - 2015
 Coached mixed gender teams from U5-U7 beginner & returning leagues
 Lead practices once to twice weekly for 2-3 teams during season
Parent Advisor for Early Childhood Education Steering Committee 2012 – 2014

3. BRYAN SOPER, PHD PAGE 3
CONGRESS PRESENTATIONS
B.R. Soper & K.V. Anderson. The role of Toll in distinguishing pathogens. Presented at 43rd
Annual Drosophila Research Conference. San Diego, CA, April 10-14, 2002. Abstract # 912
B.R. Soper & K.V. Anderson. Toll’s involvement in distinguishing pathogens. Presented at 42nd
Annual Drosophila Research Conference. Washington, DC, March 21-25, 2001. Abstract # 904
B.R. Soper & K.V. Anderson. Discovering Immunity: Identification of genes involved in
phagocytosis. Presented at 41st Annual Drosophila Research Conference. Pittsburgh, PA,
March 22-26, 2000. Abstract # 629
B.R. Soper, L. Sefton, T.W. Cline. A novel promoter for Sex-lethal?. Presented at 39th Annual
Drosophila Research Conference. Washington, DC, March, 1998.
TECHNICAL EXPERTISE/EXPERIENCE
DNA/RNA related
 PCR, RT-PCR, quantitative PCR, cloning, plasmid construction, epitope tag fusions
 Whole mount and single cell in-situ hybridizations
 Southern/Northern blots
 Comparative genomic hybridizations
 Microarray analysis
 RNA interference, siRNA, dsRNA
Animal related
 Mouse husbandry, genotyping, tissue dissection and isolation of cell types
 Single blastocyst isolations from timed pregnancies
 Reverse perfusions, IP and tail vein injections
Protein related
 Recombinant protein expression/purification
 Enzymatic activity and drug screening inhibition assays
 Western blots, SDS PAGE, ELISAs
Cell culture related
 Culturing human, murine, rodent, insect, and embryonic stem cell lines
 Homologous recombination to delete genes
 Flow cytometry, FACS to isolate single cell clones and establish cell lines
 Primary cell culture and viral transduction
 Bone marrow isolation and derivation of dendritic cells and macrophages
 Recombinant viral production for transduction
Microscopy related
 Confocal, compound, dissecting, fluorescent microscopy
 Live cell/animal imaging/video